Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study

Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study

Background: Adalimumab and ustekinumab are effective psoriasis treatments. This study compares healthcare resource utilization (HRU), costs and dose escalation and describes starting dose trends in ustekinumab versus adalimumab psoriasis patients. Methods: Adult psoriasis patients initiating adalimu...

Full description

Bibliographic Details
Main Authors: Jashin J. Wu, Annie Guérin, Geneviève Gauthier, Murali Sundaram
Format: Article
Language:English
Published: Taylor & Francis Group 2017-05-01
Series:Journal of Dermatological Treatment
Subjects:
health expenditures
medical care costs
drug costs
economics
monoclonal antibody
anti-inflammatory agent
Online Access:http://dx.doi.org/10.1080/09546634.2016.1247946

Internet

http://dx.doi.org/10.1080/09546634.2016.1247946

Similar Items